Antiangiogenic and antivascular therapy for cancer

Giulia Taraboletti, Barbara Margosio

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.

Original languageEnglish
Pages (from-to)378-384
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume1
Issue number4
DOIs
Publication statusPublished - Aug 1 2001

Fingerprint

Vascular Tissue Neoplasms
Antineoplastic Agents
Clinical Trials
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Antineoplastic therapy
  • Antivascular therapy
  • Cancer Biology
  • Growth factors
  • Inhibitors of angiogenesis
  • Matrix metalloproteinases
  • Pharmacology
  • Tumor angiogenesis
  • Vascular targeting

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Antiangiogenic and antivascular therapy for cancer. / Taraboletti, Giulia; Margosio, Barbara.

In: Current Opinion in Pharmacology, Vol. 1, No. 4, 01.08.2001, p. 378-384.

Research output: Contribution to journalArticle

@article{1bd3d695640c40a2a64207cb8ca55e17,
title = "Antiangiogenic and antivascular therapy for cancer",
abstract = "The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.",
keywords = "Antineoplastic therapy, Antivascular therapy, Cancer Biology, Growth factors, Inhibitors of angiogenesis, Matrix metalloproteinases, Pharmacology, Tumor angiogenesis, Vascular targeting",
author = "Giulia Taraboletti and Barbara Margosio",
year = "2001",
month = "8",
day = "1",
doi = "10.1016/S1471-4892(01)00065-0",
language = "English",
volume = "1",
pages = "378--384",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Antiangiogenic and antivascular therapy for cancer

AU - Taraboletti, Giulia

AU - Margosio, Barbara

PY - 2001/8/1

Y1 - 2001/8/1

N2 - The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.

AB - The great interest in the potential antineoplastic effect of targeting tumor-associated blood vessels has generated an expanding armamentarium of therapeutic tools that include antiangiogenic compounds, aimed at preventing the formation of vessels, and antivascular compounds, targeted to the existing tumor vasculature. Following promising preclinical studies, antiangiogenic drugs have rapidly gained access to clinical trials.

KW - Antineoplastic therapy

KW - Antivascular therapy

KW - Cancer Biology

KW - Growth factors

KW - Inhibitors of angiogenesis

KW - Matrix metalloproteinases

KW - Pharmacology

KW - Tumor angiogenesis

KW - Vascular targeting

UR - http://www.scopus.com/inward/record.url?scp=0035434591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035434591&partnerID=8YFLogxK

U2 - 10.1016/S1471-4892(01)00065-0

DO - 10.1016/S1471-4892(01)00065-0

M3 - Article

C2 - 11710736

AN - SCOPUS:0035434591

VL - 1

SP - 378

EP - 384

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 4

ER -